Metraipolis › archive › dc_a2f51295e5db

Cyclophosphamide for the Treatment of Refractory Immune Effector Cell-Associated Neurotoxicity Syndrome Following CD19-Targeted CAR T-Cell Therapy — Europe PMC PMID:41487336

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41487336
DOI
10.14740/jmc5211
License (as archived)
solo-consultazione
Archived
2026-11-07T10:24:38.753Z
SHA-256 of the archived text
40db9e9b04e1a0fdbf9561b8580d498b2d7f7405df75d10a98a1315fa7062269
Stable URL of this page
https://metraipolis.com/documento/dc_a2f51295e5db

How to cite

Cyclophosphamide for the Treatment of Refractory Immune Effector Cell-Associated Neurotoxicity Syndrome Following CD19-Targeted CAR T-Cell Therapy — Europe PMC PMID:41487336 — Europe PMC (en), https://europepmc.org/article/MED/41487336 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_a2f51295e5db (Metraipolis archive dc_a2f51295e5db, sha256 40db9e9b04e1a0fdbf9561b8580d498b2d7f7405df75d10a98a1315fa7062269)
BibTeX
@misc{dca2f51295e5db,
  title = {Cyclophosphamide for the Treatment of Refractory Immune Effector Cell-Associated Neurotoxicity Syndrome Following CD19-Targeted CAR T-Cell Therapy — Europe PMC PMID:41487336},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41487336},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_a2f51295e5db; sha256 40db9e9b04e1a0fdbf9561b8580d498b2d7f7405df75d10a98a1315fa7062269},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41487336. Agents can read the archived copy with the MCP tool read_document.